United States: Viking Therapeutics Announces $632.5 Million Public Offering Of Common Stock - Cooley LLP

Credit: Mondaq- Published on March 13, 2024

Cooley advised the underwriters of Viking Therapeutics (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders...